Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026

On October 19, 2026 Pliant Therapeutics, Inc. (Nasdaq: PLRX) reported a presentation at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation

Title: Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual αvβ8/αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Immune Checkpoint Inhibitor–Refractory Advanced Solid Tumours

Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: Development Therapeutics
Date and Time: Friday, October 23, 2026, 3:15 – 4:00 p.m. CEST
Location: Hall 5, Poster 1082TiP

FORTIFY – PLN-101095 Phase 1b Indication Expansion Trial

PLN-101095 is currently being evaluated in Phase 1a/1b open-label, dose-escalation and indication expansion trial (NCT06270706) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.

(Press release, Pliant Therapeutics, OCT 19, 2026, View Source [SID1234673595])